Literature DB >> 26349823

Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?

Kristina Öbrink-Hansen1, Rasmus Vestergaard Juul2, Merete Storgaard3, Marianne Kragh Thomsen4, Tore Forsingdal Hardlei5, Birgitte Brock5, Mads Kreilgaard2, Jakob Gjedsted6.   

Abstract

Antibiotic dosing in septic shock patients poses a challenge for clinicians due to the pharmacokinetic (PK) variability seen in this patient population. Piperacillin-tazobactam is often used for empirical treatment, and initial appropriate dosing is crucial for reducing mortality. Accordingly, we determined the pharmacokinetic profile of piperacillin (4 g) every 8 h, during the third consecutive dosing interval, in 15 patients treated empirically for septic shock. We developed a population pharmacokinetic model to assess empirical dosing and to simulate alternative dosing regimens and modes of administration. Time above the MIC (T>MIC) predicted for each patient was evaluated against clinical breakpoint MIC for Pseudomonas aeruginosa (16 mg/liter). Pharmacokinetic-pharmacodynamic (PK/PD) targets evaluated were 50% fT>4×MIC and 100% fT>MIC. A population PK model was developed using NONMEM, and data were best described by a two-compartment model. Central and intercompartmental clearances were 3.6 liters/h (relative standard error [RSE], 15.7%) and 6.58 liters/h (RSE, 16.4%), respectively, and central and peripheral volumes were 7.3 liters (RSE, 11.8%) and 3.9 liters (RSE, 9.7%), respectively. Piperacillin plasma concentrations varied considerably between patients and were associated with levels of plasma creatinine. Patients with impaired renal function were more likely to achieve predefined PK/PD targets than were patients with preserved or augmented renal function. Simulations of alternative dosing regimens showed that frequent intermittent bolus dosing as well as dosing by extended and continuous infusion increases the probability of attaining therapeutic plasma concentrations. For septic shock patients with preserved or augmented renal function, dose increment or prolonged infusion of the drug needs to be considered. (This study has been registered at ClinicalTrials.gov under registration no. NCT02306928.).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26349823      PMCID: PMC4604352          DOI: 10.1128/AAC.01347-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial.

Authors:  Rodger D MacArthur; Mark Miller; Timothy Albertson; Edward Panacek; David Johnson; Leah Teoh; William Barchuk
Journal:  Clin Infect Dis       Date:  2003-12-22       Impact factor: 9.079

2.  Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Authors:  Thomas P Lodise; Ben Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.

Authors:  Leonardo Lorente; Alejandro Jiménez; María M Martín; José Luis Iribarren; Juan José Jiménez; María L Mora
Journal:  Int J Antimicrob Agents       Date:  2009-01-15       Impact factor: 5.283

4.  First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.

Authors:  Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Andrew J Dalley; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2009-12-16       Impact factor: 5.283

5.  A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.

Authors:  Joel M Dulhunty; Jason A Roberts; Joshua S Davis; Steven A R Webb; Rinaldo Bellomo; Charles Gomersall; Charudatt Shirwadkar; Glenn M Eastwood; John Myburgh; David L Paterson; Therese Starr; Sanjoy K Paul; Jeffrey Lipman
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

6.  Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study.

Authors:  Angela Huttner; Elodie Von Dach; Adriana Renzoni; Benedikt D Huttner; Mathieu Affaticati; Leonardo Pagani; Yousef Daali; Jerôme Pugin; Abderrahim Karmime; Marc Fathi; Daniel Lew; Stephan Harbarth
Journal:  Int J Antimicrob Agents       Date:  2015-01-19       Impact factor: 5.283

7.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

8.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

9.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

Authors:  Peggy S McKinnon; Joseph A Paladino; Jerome J Schentag
Journal:  Int J Antimicrob Agents       Date:  2008-03-04       Impact factor: 5.283

10.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more
  13 in total

1.  Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.

Authors:  Waroonrat Sukarnjanaset; Sutep Jaruratanasirikul; Thitima Wattanavijitkul
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-08       Impact factor: 2.745

Review 2.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

3.  Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.

Authors:  Fekade Bruck Sime; Uwe Hahn; Morgyn S Warner; Ing Soo Tiong; Michael S Roberts; Jeffrey Lipman; Sandra L Peake; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?

Authors:  Maria Goul Andersen; Anders Thorsted; Merete Storgaard; Anders N Kristoffersson; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

6.  Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients.

Authors:  Ibrahim El-Haffaf; Romain Guilhaumou; Lionel Velly; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2022-03-28       Impact factor: 5.577

7.  Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment.

Authors:  Vibeke Klastrup; Anders Thorsted; Merete Storgaard; Steffen Christensen; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

8.  Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.

Authors:  Anders Thorsted; Anders N Kristoffersson; Sabine F Maarbjerg; Henrik Schrøder; Mikala Wang; Birgitte Brock; Elisabet I Nielsen; Lena E Friberg
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

9.  We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?

Authors:  Menino Osbert Cotta; Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care       Date:  2016-06-06       Impact factor: 9.097

Review 10.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.